Arrowgrass Capital Partners (US)’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-70,000	Closed	-$6.14M	–	300
2019 Q2	$6.14M	Hold	70,000	–	–	0.15%	173
2019 Q1	$6.34M	Hold	70,000	–	–	0.19%	157
2018 Q4	$5.02M	Buy	+70,000	New	+$5.64M	0.19%	139
2018 Q1	–	Sell	-4,100	Closed	-$348K	–	486
2017 Q4	$348K	Buy	4,100 +4,059	+9,900%	+$340K	﹤0.01%	472
2017 Q3	$355K	Hold	41	–	–	﹤0.01%	540
2017 Q2	$316K	Sell	41 -7	-15%	-$496	﹤0.01%	567
2017 Q1	$333K	Sell	48 -134	-74%	-$9K	﹤0.01%	533
2016 Q4	$1.08M	Sell	182 -70	-28%	-$4.32K	0.01%	425
2016 Q3	$1.67M	Buy	+252	New	+$15.6K	0.02%	318

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s XBI Position: Q4 2019 in Review

Arrowgrass Capital Partners (US) sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2019, closing a stake of 26,974 shares — an estimated $2.06M sold.

Arrowgrass Capital Partners (US) first reported a position in XBI in Q1 2017 and held it in 3 quarters. The position peaked at $2.45M in Q4 2018. 474 funds tracked by Wall St. Rank hold XBI as of Q4 2019.

Arrowgrass Capital Partners (US) reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2019 after selling out during the quarter.
Arrowgrass Capital Partners (US) sold 26,974 State Street SPDR S&P Biotech ETF shares in Q4 2019, an estimated $2.06M.
Arrowgrass Capital Partners (US) first reported a position in State Street SPDR S&P Biotech ETF in Q1 2017 and held it in 3 quarters.
Arrowgrass Capital Partners (US)'s State Street SPDR S&P Biotech ETF position peaked at $2.45M in Q4 2018.
474 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2019.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q4 2019, filed 14 Feb 2020.